Benign Prostatic Hyperplasia and Metabolic Syndrome model of spontaneous hypertension and prostate hyperplasia. J Androl 2003;24:263-9. 44. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997;21:355-9. 45. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002;52:98-105. 46. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 2008;68:1477-86. 47. Rohrmann S, Giovannucci E, Smit E, Platz EA. Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate 2007;67:1693-8. 48. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the met- abolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226-34. 49. Martin-Cordero L, Garcia JJ, Giraldo E, De la Fuente M, Manso R, Ortega E. Influence of exercise on the circulating levels and macrophage production of IL-1beta and IFNgamma affected by metabolic syndrome: an obese Zucker rat experimental animal model. Eur J Appl Physiol 2009;107:535-43. 50. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009;20:182-9. 51. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates ni- tric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9. 52. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-32. 53. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of ni- tric oxide on human and canine prostates. Urology 1995;45:440-6. 54. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circu- lation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8. 55. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ. Atherosclerosis-in- duced chronic ischemia causes bladder fibrosis and non-com- pliance in the rabbit. J Urol 1999;161:1626-35. 56. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001;165:1019-26. 57. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic is- chemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003;170:659-63. 58. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adre- nergic contraction of prostatic smooth muscle cells. J Urol 2003;170:2517-22. 59. Takahashi R, Nishimura J, Seki N, Yunoki T, Tomoda T, Kanaide H, et al. RhoA/Rho kinase-mediated Ca2+ sensitization in the con- traction of human prostate. Neurourol Urodyn 2007;26:547-51. 60. Peters SL, Schmidt M, Michel MC. Rho kinase: a target for treat- ing urinary bladder dysfunction? Trends Pharmacol Sci 2006;27:492-7. 61. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, et al. Cyclic GMP-dependent protein 515 kinase signaling pathway inhibits RhoA-induced Ca2+ sensitiza- tion of contraction in vascular smooth muscle. J Biol Chem 2000;275:21722-9. 62. Zozuliñska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in di- abetic patients. Diabetologia 1999;42:117-8. 63. Khan ZA, Chakrabarti S. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol 2003;81:622-34. 64. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, et al. The vitamin D receptor agonist elocalcitol in- hibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009;69: 480-93. 65. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276-83. 66. Murdolo G, Smith U. The dysregulated adipose tissue: a connect- ing link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis 2006;16:S35-8. 67. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006;1084:89-117. 68. Trayhurn P, Wood IS. Adipokines: inflammation and the pleio- tropic role of white adipose tissue. Br J Nutr 2004;92:347-55. 69. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 pa- tients' immunohistochemical analysis. Prostate 2009;69:1774-80. 70. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic in- flammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-88. 71. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51:524-33. 72. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007;69:708-13. 73. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397-402. 74. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hor- mone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40-9. 75. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improve- ment of the metabolic syndrome and lower urinary tract symp- toms upon normalisation of plasma testosterone levels in hypo- gonadal elderly men. Andrologia 2009;41:7-13. 76. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57-61. 77. Ansari MA, Begum D, Islam F. Serum sex steroids, gonado- trophins and sex hormone-binding globulin in prostatic hyperplasia. Ann Saudi Med 2008;28:174-8. 78. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ. Serum sex hormones and measures of benign pro- Korean J Urol 2011;52:507-516